BridGene Biosciences Raises $28M Series B+ Led by Bayland Capital

Deal Summary

BridGene Biosciences closed a $28M Series B+ financing led by Bayland Capital with participation from GTJA Investment Group, Proxima Ventures, and existing investors Lapam Capital and Grains Valley Venture Capital. The funds will support the company's discovery and development of small-molecule drugs for hard-to-drug targets.